Compare GEL & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEL | TYRA |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1996 | 2021 |
| Metric | GEL | TYRA |
|---|---|---|
| Price | $17.09 | $34.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $19.50 | ★ $47.50 |
| AVG Volume (30 Days) | 231.9K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,912,770,000.00 | N/A |
| Revenue This Year | $12.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 43.60 | N/A |
| 52 Week Low | $13.21 | $8.75 |
| 52 Week High | $18.64 | $40.65 |
| Indicator | GEL | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 41.73 |
| Support Level | $16.28 | $33.81 |
| Resistance Level | $17.73 | $39.90 |
| Average True Range (ATR) | 0.48 | 2.09 |
| MACD | -0.02 | -0.24 |
| Stochastic Oscillator | 36.05 | 13.28 |
Genesis Energy LP focuses on the midstream segment of the crude oil and natural gas industry. It offers various services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are: Offshore pipeline transportation, Marine transportation, and Onshore transportation and services. Maximum revenue is generated from the Offshore pipeline transportation segment, which includes the transportation and processing of crude oil and natural gas in the Gulf of America. The Marine transportation segment provides waterborne transportation of petroleum products and crude oil throughout North America; and the Onshore transportation and services segment deals with crude oil logistics, sour gas processing, and sells sulfur byproducts.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.